<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997542</url>
  </required_header>
  <id_info>
    <org_study_id>97-044</org_study_id>
    <nct_id>NCT00997542</nct_id>
  </id_info>
  <brief_title>Allopurinol in Chronic Heart Failure</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Cross-over Study of the Effects of Allopurinol on Oxidative Metabolism, Peripheral Blood Flow and Immune Function in Patients With Advanced Chronic Heart Failure (CHF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart and Lung Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart and Lung Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to discover whether the inhibition of the xanthine oxidase with&#xD;
      allopurinol leads to a reduction of the production of oxygen free radicals in patients with&#xD;
      CHF and thereby improves characteristics of oxydative metabolism, peripheral blood flow,&#xD;
      immune function and functional status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postischemic peak peripheral blood flow</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is a male and at least 21 years of age.&#xD;
&#xD;
          -  The patient has clinical evidence of heart failure: a) reduced ejection fraction&#xD;
             (≤40%) or cardiomegaly on CXR or left ventricular impairment on echocardiography&#xD;
             (LVEDD ≥60mm), b) stable clinical condition and medication for at least 1 month prior&#xD;
             to the study.&#xD;
&#xD;
          -  No history of unstable angina, myocardial infarction or stroke within 3 months prior&#xD;
             to the study.&#xD;
&#xD;
          -  The patient is receiving full conventional medical therapy for heart failure (ACE&#xD;
             inhibitor or angiotensin II blocker, diuretics etc.).&#xD;
&#xD;
          -  The patient is willing and capable of complying with the requirements of this&#xD;
             protocol.&#xD;
&#xD;
          -  The patient has provided written informed consent .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has any life-threatening disease, other than heart failure (including&#xD;
             patients with known, or suspected, myocarditis or with automatic implantable&#xD;
             cardioverter/defibrillators).&#xD;
&#xD;
          -  The patient has an active malignancy of any type, or history of a malignancy (Patients&#xD;
             who have a history of basal cell carcinoma that has been surgically removed are&#xD;
             acceptable). Patients with a history of other malignancies that have been surgically&#xD;
             removed and who have no evidence of recurrence for at least five years prior to study&#xD;
             enrolment are also acceptable.&#xD;
&#xD;
          -  The patient has had a heart transplant.&#xD;
&#xD;
          -  The patient has severe renal disease (S-Creatinine &gt;300 μmol/l), severe liver disease&#xD;
             (ASAT or ALAT &gt; 3 times of upper limit of normal range), rheumatoid arthritis, or&#xD;
             complains of gout.&#xD;
&#xD;
          -  The patients has received allopurinol therapy previously or if he is known to suffer&#xD;
             from gout (acutely or chronically).&#xD;
&#xD;
          -  The patient has an exercise capacity of &gt; 20 ml/kg/min (treadmill, Bruce protocol) or&#xD;
             is in functional NYHA class I.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>October 16, 2009</last_update_submitted>
  <last_update_submitted_qc>October 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

